BLPH

Bellerophon Therapeutics, Inc. [BLPH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BLPH Stock Summary

Top 10 Correlated ETFs

BLPH


Top 10 Correlated Stocks

BLPH


In the News

09:57 22 Mar 2023 BLPH

Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going

Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

06:00 22 Mar 2023 BLPH

How to Find Cheap Penny Stocks to Make Money Trading

Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:39 22 Mar 2023 BLPH

5 Hot Penny Stocks Exploding After News This Week

Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

02:18 22 Mar 2023 BLPH

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

07:00 22 Mar 2023 BLPH

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

06:47 22 Mar 2023 BLPH

Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped

The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.

01:12 22 Mar 2023 BLPH

These Biotech Penny Stocks Exploded Today, Here's Why

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:30 22 Mar 2023 BLPH

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

08:30 22 Mar 2023 BLPH

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

01:22 22 Mar 2023 BLPH

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

BLPH Financial details

Company Rating
Neutral
Market Cap
67.6M
Income
-14.82M
Revenue
0
Book val./share
0.78
Cash/share
1.19
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
29 Mar 2023
P/E
-4.63
Forward P/E
-
PEG
0.91
P/S
-
P/B
9.24
P/C
6.04
P/FCF
-4.32
Quick Ratio
2.19
Current Ratio
2.33
Debt / Equity
0.7
LT Debt / Equity
-
-
-
EPS (TTM)
-1.55
EPS next Y
-
EPS next Q
-
EPS this Y
-41.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
23.26%
-
-
-
-
SMA20
600%
SMA50
250%
SMA100
600%
Inst Own
9.69%
Inst Trans
-1.66%
ROA
-118%
ROE
-103%
ROC
-2.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
10.45M
Shs Float
5.89M
-
-
-
-
Target Price
19
52W Range
0.67-7.88
52W High
-
52W Low
-
RSI
79
Rel Volume
0.11
Avg Volume
2.27M
Volume
257.12K
Perf Week
5.35%
Perf Month
333.13%
Perf Quarter
598.06%
Perf Half Y
509.32%
-
-
-
-
Beta
0.346545
-
-
Volatility
0.35%, 2.55%
Prev Close
0%
Price
7.19
Change
-6.01%

BLPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
000-3.170
Operating cash flow per share
-6.06-4.05-2.87-2.55-2.4
Free cash flow per share
-6.06-4.05-2.87-2.55-2.4
Cash per share
12.254.352.196.12.6
Book value per share
-11.010.84.912.28
Tangible book value per share
-11.010.84.912.28
Share holders equity per share
-11.010.84.912.28
Interest debt per share
000.150.120.1
Market cap
100.49M46.04M23.62M52.01M29.46M
Enterprise value
71.67M29.39M16.07M6.11M5.68M
P/E ratio
000-2.10
Price to sales ratio
00000
POCF ratio
-6.38-2.97-1.83-2.62-1.29
PFCF ratio
-6.38-2.97-1.83-2.62-1.29
P/B Ratio
-38.7411.946.581.361.36
PTB ratio
-38.7411.946.581.361.36
EV to sales
00000
Enterprise value over EBITDA
000-0.23-0.28
EV to operating cash flow
-4.55-1.9-1.24-0.31-0.25
EV to free cash flow
-4.55-1.9-1.24-0.31-0.25
Earnings yield
000-0.480
Free cash flow yield
-0.16-0.34-0.55-0.38-0.77
Debt to equity
-15.193.762.650.310.24
Debt to assets
1.070.790.730.240.2
Net debt to EBITDA
0001.731.19
Current ratio
5.032.311.374.615.04
Interest coverage
000-105.1-4.03K
Income quality
0000.80
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
00018.710
ROIC
0000.50
Return on tangible assets
000-0.490
Graham Net
-2.920.560.084.562.05
Working capital
28.5M9.86M2.8M37.65M20.41M
Tangible asset value
-2.59M3.86M3.59M38.25M21.62M
Net current asset value
-3.82M2.89M865K36.09M20.2M
Invested capital
000.180.020.04
Average receivables
00000
Average payables
3.33M3.3M2.93M3.42M2.46M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
000-0.650
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-0.490-0.59-0.43-0.53
Operating cash flow per share
-0.59-0.42-0.5-0.38-0.52
Free cash flow per share
-0.59-0.42-0.5-0.38-0.52
Cash per share
3.022.62.11.711.19
Book value per share
2.712.271.691.290.78
Tangible book value per share
2.712.271.691.290.78
Share holders equity per share
2.712.271.691.290.78
Interest debt per share
0.120.10.080.060.05
Market cap
38.6M29.47M22.53M11.74M10.4M
Enterprise value
11.02M5.69M3.3M-4M-516.46K
P/E ratio
-2.080-1-0.72-0.51
Price to sales ratio
00000
POCF ratio
-6.91-7.41-4.76-3.2-2.08
PFCF ratio
-6.91-7.41-4.76-3.2-2.08
P/B Ratio
1.51.361.390.961.4
PTB ratio
1.51.361.390.961.4
EV to sales
00000
Enterprise value over EBITDA
-2.39-1.34-0.590.620.1
EV to operating cash flow
-1.97-1.43-0.71.090.1
EV to free cash flow
-1.97-1.43-0.71.090.1
Earnings yield
-0.120-0.25-0.35-0.49
Free cash flow yield
-0.14-0.13-0.21-0.31-0.48
Debt to equity
0.210.240.340.440.7
Debt to assets
0.180.20.260.310.41
Net debt to EBITDA
5.985.593.422.432.18
Current ratio
5.85.043.693.122.33
Interest coverage
0-854.6-5.64K-344.26-108.85
Income quality
1.2100.840.890.99
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
5.4504.753.533.05
ROIC
0.180.140.280.240.44
Return on tangible assets
-0.150-0.26-0.23-0.4
Graham Net
2.442.051.511.140.64
Working capital
24.59M20.41M14.95M11.54M6.88M
Tangible asset value
25.79M21.62M16.17M12.28M7.43M
Net current asset value
24.19M20.2M14.94M11.54M6.88M
Invested capital
0.040.040.050.050.05
Average receivables
00000
Average payables
1.88M1.24M1.69M2.1M1.77M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.180-0.35-0.33-0.68
Capex per share
00000

BLPH Frequently Asked Questions

What is Bellerophon Therapeutics, Inc. stock symbol ?

Bellerophon Therapeutics, Inc. is a US stock , located in Warren of Nj and trading under the symbol BLPH

What is Bellerophon Therapeutics, Inc. stock quote today ?

Bellerophon Therapeutics, Inc. stock price is $7.19 today.

Is Bellerophon Therapeutics, Inc. stock public?

Yes, Bellerophon Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap